<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JDR</journal-id>
<journal-id journal-id-type="hwp">spjdr</journal-id>
<journal-id journal-id-type="nlm-ta">J Dent Res</journal-id>
<journal-title>Journal of Dental Research</journal-title>
<issn pub-type="ppub">0022-0345</issn>
<issn pub-type="epub">1544-0591</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0022034511435260</article-id>
<article-id pub-id-type="publisher-id">10.1177_0022034511435260</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
<subj-group subj-group-type="heading">
<subject>Critical Reviews in Oral Biology &amp; Medicine</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Osteoinduction</article-title>
<subtitle>A Review of Old Concepts with New Standards</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Miron</surname><given-names>R.J.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034511435260">1</xref>
<xref ref-type="aff" rid="aff2-0022034511435260">2</xref>
<xref ref-type="corresp" rid="corresp1-0022034511435260">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Y.F.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034511435260">1</xref>
<xref ref-type="corresp" rid="corresp1-0022034511435260">*</xref>
</contrib>
</contrib-group>
<aff id="aff1-0022034511435260"><label>1</label>The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) &amp; Key Laboratory of Oral Biomedicine, Ministry of Education, School &amp; Hospital of Stomatology, Wuhan University, 237 LuoYu Road, Wuhan, 430079, China</aff>
<aff id="aff2-0022034511435260"><label>2</label>Faculté de médecine dentaire, Pavillon de médecine dentaire, rue de la Terrasse, Université Laval, Québec, Canada</aff>
<author-notes>
<corresp id="corresp1-0022034511435260"><label>*</label><email>richard.miron.1@ulaval.ca</email> and <email>zyf@whu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>91</volume>
<issue>8</issue>
<fpage>736</fpage>
<lpage>744</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 International &amp; American Associations for Dental Research</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">International &amp; American Associations for Dental Research</copyright-holder>
</permissions>
<abstract>
<p>Since the discovery of osteoinduction in the early 20th century, innovative biomaterials with osteoinductive potential have emerged. Over the last 50 years, however, our ability to describe biological phenomena accurately has been improved dramatically by advancements in cell and molecular biology. The aim of this review is to divide the osteoinduction phenomenon into 3 principles: (1) mesenchymal cell recruitment, (2) mesenchymal differentiation to bone-forming osteoblasts, and (3) ectopic bone formation <italic>in vivo</italic>. Furthermore, this review formulates guidelines for <italic>in vitro</italic> and <italic>in vivo</italic> experimental testing for accurately defining new biomaterials as osteoinductive. The use of growth factors with osteoinductive potential in periodontal and oral surgery is discussed. These concepts and guidelines aim to guide the future direction of emerging biomaterials in bone regeneration.</p>
</abstract>
<kwd-group>
<kwd>PDGF</kwd>
<kwd>BMP</kwd>
<kwd>bone regeneration</kwd>
<kwd>bone remodeling</kwd>
<kwd>osteoinduction</kwd>
<kwd>bone grafts</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0022034511435260">
<title>Overview</title>
<p>From the discovery of bone morphogenic proteins (<xref ref-type="bibr" rid="bibr77-0022034511435260">Urist and Strates, 1971</xref>) to the advancements in tissue engineering (<xref ref-type="bibr" rid="bibr42-0022034511435260">Langer, 2009</xref>), the field of bone regeneration has tackled a wide variety of surgical issues caused by trauma, bone loss diseases, infections, biochemical disorders, and abnormal skeletal development. One such discipline which applies the principles of biology to the development of viable substitutes is the domain of biomaterials, which is an emerging interdisciplinary field aimed to restore, maintain, or improve the function of human tissues (<xref ref-type="bibr" rid="bibr4-0022034511435260">Anderson <italic>et al</italic>., 2004</xref>). Over the years, the role of biomaterials has changed from a passive, structural supporting network to one that will orchestrate the process of tissue engineering. These are best exemplified in bone-grafting procedures, more than 2.2 million of which are performed yearly at an estimated global cost approaching $2.5 billion annually (<xref ref-type="bibr" rid="bibr27-0022034511435260">Giannoudis <italic>et al</italic>., 2005</xref>). As the population ages, the number of bone-grafting procedures for diseases such as osteoporosis, arthritis, tumors, and trauma also increases, placing an even larger demand on the healthcare system to replace and restore lost bone. With markets increasing by over 50% annually and sales of regenerative biomaterials exceeding US$240 million <italic>per annum</italic> (<xref ref-type="bibr" rid="bibr63-0022034511435260">Place <italic>et al</italic>., 2009</xref>), improved understanding of fundamental concepts is necessary.</p>
<p>The regenerative potential of bone grafts is governed by 3 fundamental mechanisms. The ideal grafting material should provide:</p>
<list id="list1-0022034511435260" list-type="simple">
<list-item><p>(1) an osteoconductive matrix, which allows for vascular invasion and cellular infiltration;</p></list-item>
<list-item><p>(2) osteoinductive factors, which recruit and induce mesenchymal cells to differentiate into mature bone-forming cells; and</p></list-item>
<list-item><p>(3) osteogenic cells, contained inside the bone graft, capable of laying new bone matrix.</p></list-item>
</list>
<p>Consequently, the gold standard for bone-grafting procedures is autogenous bone because of its excellent combination of osteoconduction and osteoinduction. Despite their benefits, limitations of additional surgical procedures and donor site morbidity have necessitated the pursuit of alternatives. These include freeze-dried bone allografts from human donors, xenografts from animal models, and an array of synthetic alloplasts such as hydroxyapatite, βTCP, polymers, and bioactive glass (<xref ref-type="bibr" rid="bibr38-0022034511435260">Kao and Scott, 2007</xref>). Other strategies incorporate growth-factor- and cell-based alternatives used either alone or in combination with other materials (<xref ref-type="bibr" rid="bibr35-0022034511435260">Jabbarzadeh <italic>et al</italic>., 2008</xref>). Although most of these materials are osteoconductive to bone-forming osteoblasts, only a limited number of osteoinductive materials are currently available on the market with FDA approval (<xref ref-type="table" rid="table1-0022034511435260">Table 1</xref>). Many investigators have aimed to generate new biomaterials with osteoinductive potential; however, a fundamental understanding of the term is of critical importance. The aim of this review is to clarify the original definition as presented by Marshall Urist in <xref ref-type="bibr" rid="bibr75-0022034511435260">1965</xref>, to generate new insights with the aid of advancements in cell biology over the last 50 years, and to list necessary <italic>in vitro</italic> and <italic>in vivo</italic> experiments for the accurate definition of new biomaterials as osteoinductive.</p>
<table-wrap id="table1-0022034511435260" position="float">
<label>Table 1.</label>
<caption>
<p>The Osteoinductive Bone Grafts Approved by the US FDA and the EU</p>
</caption>
<graphic alternate-form-of="table1-0022034511435260" xlink:href="10.1177_0022034511435260-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Marketing Year</th>
<th align="center">Product Name</th>
<th align="center">Composition</th>
<th align="center">Clinical Phase</th>
<th align="center">Company</th>
<th align="center">Approved by</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>DBX</td>
<td>Demineralized bone matrix (DBM) in sodium hyaluronate carrier</td>
<td>On market</td>
<td>MTF (Edison, NJ, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2001</td>
<td>Collagraft</td>
<td>65% hydroxyapatite, 35% tricalcium phosphate and bovine collagen</td>
<td>On market</td>
<td>Neucoll (Campbell, CA, USA)</td>
<td>US FDA and EU</td>
</tr>
<tr>
<td>2001</td>
<td>Tutoplast®</td>
<td>Allograft bone</td>
<td>On market</td>
<td>Tutogen Medicals (Clifton, NJ,USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2002</td>
<td>INFUSE® Bone Graft</td>
<td>Bone morphogenetic protein-2 (BMP-2) in absorbable collagen sponge</td>
<td>On market</td>
<td>Medtronic (Minneapolis, MN, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2002</td>
<td>DynaGraft®</td>
<td>Demineralized bone matrix (DBM) mixed with temp. sensitive polymer</td>
<td>On market</td>
<td>IsoTis (Irvine, CA,USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2004</td>
<td>InductOs®</td>
<td>Human bone morphogenetic protein-2 (BMP-2) in bovine collagen sponge carrier</td>
<td>On market</td>
<td>Wyeth Pharmaceuticals (NewLane Havant, Hants, UK)</td>
<td>US FDA and EU</td>
</tr>
<tr>
<td>2004</td>
<td>Allomatrix</td>
<td>Demineralized bone matrix (DBM) and cancellous bone chips with calcium sulfate carrier</td>
<td>On market</td>
<td>Wright Medical (Arlington, TN, USA)</td>
<td>US FDA and EU</td>
</tr>
<tr>
<td>2005</td>
<td>OrthoBlast®~II</td>
<td>Demineralized bone matrix (DBM)</td>
<td>On market</td>
<td>lsoTis OrthoBiologics, Inc. (Irvine, CA, USA)</td>
<td>US FDA and EU</td>
</tr>
<tr>
<td>2005</td>
<td>Grafton</td>
<td>Demineralized bone matrix (DBM) fibers with glycerol carrier</td>
<td>On market</td>
<td>Osteotech (Eatontown, NJ, USA)</td>
<td>US FDA and EU</td>
</tr>
<tr>
<td>2005</td>
<td>Osteofil®</td>
<td>Demineralized bone matrix (DBM) particulate with porcine collagen carrier</td>
<td>On market</td>
<td>Regeneration Technology (Alachua, FL, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2005</td>
<td>InterGro®DBM</td>
<td>Demineralized allograft bone in lipid carrier</td>
<td>On market</td>
<td>Interpore Cross International (Irvine, CA, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2007</td>
<td>NuBone™</td>
<td>Allograft tissue (demineralized bone matrix [(DBM)] combined with cortical bone gelatin carrier)</td>
<td>On market</td>
<td>Globus Medical, Inc. (Audubon, PA, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2008</td>
<td>OraGRAFT®</td>
<td>Demineralized Freeze-dried Bone Allograft</td>
<td>On market</td>
<td>LifeNet Health, Inc. (Virginia Beach, VA, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2009</td>
<td>Pro-Stim Injectable Inductive Graft</td>
<td>Calcium sulfate and calcium phosphate materials with osteoinductive demineralized bone matrix</td>
<td>On market</td>
<td>Wright Medical Group (Arlington, TN, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2009</td>
<td>EquivaBone®</td>
<td>Osteoinductive Demineralized Bone Matrix (DBM) and osteoconductive nanocrystalline calcium phosphate</td>
<td>On market</td>
<td>ETEX Corporation (Cambridge, MA, USA)</td>
<td>US FDA</td>
</tr>
<tr>
<td>2010</td>
<td>OP-1™</td>
<td>Combination of Osteogenic Protein 1 and a collagen carrier</td>
<td>On market</td>
<td>Stryker (Kalamazoo, MI, USA)</td>
<td>US FDA and EU</td>
</tr>
<tr>
<td>2011</td>
<td>Accell TBM (R)</td>
<td>Demineralized bone matrix (DBM)</td>
<td>On market</td>
<td>Integra LifeSciences Holdings Corporation (Plainsboro, NJ, USA)</td>
<td>US FDA</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section2-0022034511435260">
<title>Osteoinduction as Originally Defined</title>
<p>Historically, osteoinduction refers to the process by which one tissue, or product derived from it, causes a second undifferentiated tissue to differentiate into bone. The earliest proof of bone induction was observed in autoimplantation of transitional epithelium of the urinary bladder to the abdominal wall muscles in dogs (<xref ref-type="bibr" rid="bibr33-0022034511435260">Huggins, 1931</xref>). This discovery was further investigated by <xref ref-type="bibr" rid="bibr47-0022034511435260">Levander (1938)</xref>, who demonstrated that crude alcoholic extracts of bone induced bone formation when injected into muscle tissue. Over the following 20 years, many authors investigated the osteoinductive phenomenon by studying implantation of bone by methods of demineralization into various body organs to test for an osteopromotive effect. In a classic study by Urist in <xref ref-type="bibr" rid="bibr75-0022034511435260">1965</xref>, he described ‘autoinduction’ by studying the ability of demineralized bone matrix to induce in-growth of connective tissue and differentiation of cartilage and bone when implanted into extraskeletal locations in rabbits, dogs, and rats. Subsequent investigations from Urist and Reddi demonstrated that low-molecular-weight proteins extracted from demineralized bone matrix (DBM), termed bone morphogenetic proteins (BMPs), showed more osteogenic activity than DBM alone. The original definition of osteoinduction was defined as “the mechanism of cellular differentiation toward bone of one tissue due to physicochemical effect or contact with another tissue” (<xref ref-type="bibr" rid="bibr78-0022034511435260">Urist <italic>et al</italic>., 1967</xref>).</p>
</sec>
<sec id="section3-0022034511435260">
<title>The Ideal Osteoinductive Material</title>
<p>To maximize the potential of osteoinductive biomaterials, the osteoinduction phenomenon is divided into 3 individual mechanisms/principles (<xref ref-type="fig" rid="fig1-0022034511435260">Fig. 1</xref>). As defined by Urist, an osteoinductive material should first be capable of recruiting mesenchymal-type osteoprogenitor cells. Investigators’ ability to study migration patterns, growth factor and cytokine release, as well as behavioral cell analysis has drastically improved over the last 40 years and will be addressed as Principle One. Second, the ideal osteoinductive material should be capable of transforming an undifferentiated mesenchymal cell into a mature, bone-forming osteoblast. For this to occur, an understanding of mesenchymal differentiation to cartilage and bone is summarized as Principle Two. Last, the ideal osteoinductive material should be capable of inducing in-growth ectopic bone formation when implanted into extraskeletal locations. This phenomenon will be addressed as Principle Three. The future design of new osteoinductive biomaterials aimed to maximize these components will ultimately generate the next generation of innovative biomaterials.</p>
<fig id="fig1-0022034511435260" position="float">
<label>Figure 1.</label>
<caption>
<p>Principles of osteoinductive materials. Principle 1: Osteoinductive materials should be capable of recruiting MSCs to bone graft surfaces through growth factor release. Principle 2: The material should promote MSC differentiation into osteoblasts. Principle 3: Osteoblasts must be capable of forming ectopic bone <italic>in vivo</italic>.</p>
</caption>
<graphic xlink:href="10.1177_0022034511435260-fig1.tif"/>
</fig>
</sec>
<sec id="section4-0022034511435260">
<title>Osteoinductive Principle 1: MSC Recruitment</title>
<p>Over 40 years ago, Friedenstein first reported evidence of multipotential mesenchymal cells (MSCs) that were isolated from bone marrow and formed fibroblast-like colonies with multipotential to differentiate into adipocytes, chondrocytes, osteoblasts, and myoblasts (<xref ref-type="bibr" rid="bibr25-0022034511435260">Friedenstein <italic>et al</italic>., 1970</xref>). Since then, research focused on stem cells has gathered tremendous momentum. MSCs have now been identified not only in mesodermal tissues (bone marrow, trabecular bone, synovium, cartilage, fat, muscle, and tonsil) but also in endoderm (thymus, liver)- and ectoderm (skin, hair follicle, dura mater, and dental pulp)-derived tissues (<xref ref-type="bibr" rid="bibr62-0022034511435260">Phinney and Prockop, 2007</xref>). They are a heterogeneous population of pluripotent progenitor cells that are now capable of differentiating into osteoblasts, chondrocytes, adipocytes, myocytes,cardiomyocytes, fibroblasts, myofibroblasts, epithelial cells, and neurons (<xref ref-type="bibr" rid="bibr50-0022034511435260">Liu <italic>et al</italic>., 2009</xref>).</p>
<p>Currently, MSCs are defined by an array of phenotypic markers and ability for multipotential differentiation, as defined in a position paper (<xref ref-type="bibr" rid="bibr32-0022034511435260">Horwitz <italic>et al</italic>., 2005</xref>). The International Society for Cellular Therapy has provided the following minimal criteria for defining multipotential MSCs:</p>
<list id="list2-0022034511435260" list-type="simple">
<list-item><p>(1) plastic-adherent under standard culture conditions;</p></list-item>
<list-item><p>(2) positive for CD105, CD73, and CD90 and negative for CD34, CD45, CD11a, CD19, and HLA-DR; and</p></list-item>
<list-item><p>(3) under standard differentiation conditions, MSCs should differentiate into osteocytes, adipocytes, and chondrocytes <italic>in vitro</italic>.</p></list-item>
</list>
<p>Due to a growing interest in MSC cell-based therapy (<xref ref-type="bibr" rid="bibr19-0022034511435260">De Bari and Dell’accio, 2008</xref>), a plethora of research and clinical trials has generated enormous advances in our current understanding. Initially, MSCs were tested in cancer therapy by the addition of expanded human MSCs to bone marrow transplantations, with the assumption that MSCs could rejuvenate the bone marrow stroma of chemotherapy-/radiation-treated patients (<xref ref-type="bibr" rid="bibr44-0022034511435260">Lazarus <italic>et al</italic>., 1995</xref>, <xref ref-type="bibr" rid="bibr45-0022034511435260">2005</xref>). Since then, MSCs have been used to treat heart infarct ischemia, stroke ischemia, meniscus regeneration, tendinitis, spinal cord interruption (contusion or cuts), and repair of damaged cartilage, bone, and muscle (<xref ref-type="bibr" rid="bibr7-0022034511435260">Barry and Murphy, 2004</xref>; <xref ref-type="bibr" rid="bibr19-0022034511435260">De Bari and Dell’accio, 2008</xref>). It has long been believed that growth factors also have the potential to accelerate healing and tissue regeneration in challenging scenarios by recruiting MSCs to sites of injury (<xref ref-type="bibr" rid="bibr36-0022034511435260">Kaigler <italic>et al</italic>., 2011</xref>). Although the precise molecular mechanisms that govern MSC migration to sites of injury are not yet fully understood (<xref ref-type="bibr" rid="bibr52-0022034511435260">Mendez-Ferrer <italic>et al</italic>., 2010</xref>), the study of leukocyte migration (<xref ref-type="bibr" rid="bibr31-0022034511435260">Heinzel <italic>et al</italic>., 2007</xref>) and fracture healing (<xref ref-type="bibr" rid="bibr2-0022034511435260">Ai-Aql <italic>et al</italic>., 2008</xref>) has provided a paradigm for MSC homing. During fracture healing, several growth factors, including BMPs as well as platelet-derived growth factors (PDGFs), have been shown to rapidly stimulate MSC recruitment to sites of injury (<xref ref-type="bibr" rid="bibr2-0022034511435260">Ai-Aql <italic>et al</italic>., 2008</xref>).</p>
<p>BMPs are pleiotropic morphogens that induce a sequential cascade of events, including chemotaxis, regulation of growth, differentiation, angiogenesis, and apoptosis (<xref ref-type="bibr" rid="bibr49-0022034511435260">Lissenberg-Thunnissen <italic>et al</italic>., 2011</xref>). <italic>In vitro</italic> and <italic>in vivo</italic> studies have demonstrated that BMPs are capable of enhancing osteoinductivity of MSCs and regulate their proliferation and differentiation into osteoblasts, making them well suitable for osteoinductive materials (<xref ref-type="bibr" rid="bibr49-0022034511435260">Lissenberg-Thunnissen <italic>et al</italic>., 2011</xref>). The ability of BMPs to recruit MSCs and osteoblasts has been demonstrated with modified chemotaxis Boyden and Dunn chemotaxis chambers (<xref ref-type="bibr" rid="bibr48-0022034511435260">Li <italic>et al</italic>., 2005</xref>; <xref ref-type="bibr" rid="bibr28-0022034511435260">Gonnerman <italic>et al</italic>., 2006</xref>). Another growth factor capable of rapid recruitment of MSCs is PDGF, which is available in different forms, including PDGF-AA, -AB, and -BB (<xref ref-type="bibr" rid="bibr3-0022034511435260">Alvarez <italic>et al</italic>., 2006</xref>). Once released from platelets, it acts in sites of injury by promoting rapid cell migration and proliferation (<xref ref-type="bibr" rid="bibr67-0022034511435260">Ronnstrand and Heldin, 2001</xref>). Many studies have demonstrated its role as a potent chemotactic factor for gingival and PDL fibroblasts, cementoblasts, and osteoblasts (<xref ref-type="bibr" rid="bibr36-0022034511435260">Kaigler <italic>et al</italic>., 2011</xref>). Primary human MSCs were examined for chemotaxis, and results were expressed as a chemotactic index (CI) (<xref ref-type="bibr" rid="bibr22-0022034511435260">Fiedler <italic>et al</italic>., 2002</xref>). The increase of CI was up to 3.5-fold for rhBMP-2, 3.6-fold for rhBMP-4, and up to 22-fold for rhPDGF-bb, demonstrating the ability for PDGF to drastically stimulate recruitment of MSCs to sites of injury.</p>
</sec>
<sec id="section5-0022034511435260">
<title>Osteoinduction Principle 2: MSC Differentiation to Osteoblasts</title>
<p>Although the differentiation of bone of mesenchymal origin is a complex and still unresolved topic, the aims of this article are to summarize present literature which supports the differentiation of mature osteoblasts (<xref ref-type="bibr" rid="bibr56-0022034511435260">Nombela-Arrieta <italic>et al</italic>., 2011</xref>).</p>
<p>Osteoblasts are derived from mesenchymal stem cells that can also give rise to myoblasts, adipocytes, and chondrocytes (<xref ref-type="bibr" rid="bibr21-0022034511435260">Ducy <italic>et al</italic>., 2000</xref>). Mesenchymal differentiation to osteoblasts requires the expression of 2 essential transcription factors: Runt-related transcription factor 2 (Runx2) (<xref ref-type="bibr" rid="bibr5-0022034511435260">Banerjee <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="bibr20-0022034511435260">Ducy <italic>et al</italic>., 1997</xref>) and osterix (<xref ref-type="bibr" rid="bibr55-0022034511435260">Nakashima <italic>et al</italic>., 2002</xref>). The importance of Runx2 became apparent from the Runx2-null mouse, which had a cartilaginous skeleton and a complete absence of osteoblasts (<xref ref-type="bibr" rid="bibr5-0022034511435260">Banerjee <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="bibr20-0022034511435260">Ducy <italic>et al</italic>., 1997</xref>). The osteoblasts from these knockout mice were incapable of entering the mineralization cycle required for bone formation (<xref ref-type="bibr" rid="bibr20-0022034511435260">Ducy <italic>et al</italic>., 1997</xref>). Osterix is a zinc-finger-like factor containing protein which is induced by BMPs. Knockout mice develop perfectly patterned skeletons that lack bone and are composed entirely of cartilage. Osterix was determined to act downstream of Runx2; this was discovered through a lack of expression of osterix in the Runx2 knockout mice, while the expression of Runx2 is present in osterix knockout animals (<xref ref-type="bibr" rid="bibr55-0022034511435260">Nakashima <italic>et al</italic>., 2002</xref>). Runx2 is considered by many to be the ‘master gene’ for osteoblast differentiation, because it regulates the differentiation of mesenchymal progenitor cells to pre-osteoblasts and is required for the expression of non-collagenous proteins such as bone sialoprotein (BSP) and osteocalcin (OC) (<xref ref-type="fig" rid="fig2-0022034511435260">Fig. 2</xref>). These osteoprogenitor cells begin to produce collagen 1, the most abundant collagen in the body, which provides the structural framework by allowing for dispersion of pressure, torsion, and tension resulting from movement and normal activity (<xref ref-type="bibr" rid="bibr9-0022034511435260">Boskey <italic>et al</italic>., 1999</xref>).</p>
<fig id="fig2-0022034511435260" position="float">
<label>Figure 2.</label>
<caption>
<p>A list of differentiation markers for MSCs, pre-osteoblasts, osteoblasts, and osteocytes during MSC differentiation to osteoblasts and osteocytes.</p>
</caption>
<graphic xlink:href="10.1177_0022034511435260-fig2.tif"/>
</fig>
<p>Osteoprogenitor cells partially differentiate to pre-osteoblasts, which are characterized by their expression of alkaline phosphatase (ALP), an early marker of osteoblast differentiation (<xref ref-type="bibr" rid="bibr73-0022034511435260">Tenenbaum, 1987</xref>). <italic>In vitro</italic> experiments have demonstrated that ALP participates in the initiation of mineralization (<xref ref-type="bibr" rid="bibr73-0022034511435260">Tenenbaum, 1987</xref>; <xref ref-type="bibr" rid="bibr81-0022034511435260">Wennberg <italic>et al</italic>., 2000</xref>). When pre-osteoblasts transform to fully differentiated osteoblasts, elevated expression of BSP and OC occurs (<xref ref-type="fig" rid="fig2-0022034511435260">Fig. 2</xref>). BSP is a non-collagenous protein with a molecular weight of 70-80 kDa and accounts for approximately 5 to 10% of the non-collagenous proteins of the bone extracellular matrix (<xref ref-type="bibr" rid="bibr59-0022034511435260">Oldberg <italic>et al</italic>., 1986</xref>, <xref ref-type="bibr" rid="bibr60-0022034511435260">1988</xref>; <xref ref-type="bibr" rid="bibr24-0022034511435260">Fisher <italic>et al</italic>., 1990</xref>). It preferentially binds to collagen I and nucleates hydroxyapatite crystal formation, indicating a role in the initial mineralization of bone (<xref ref-type="bibr" rid="bibr74-0022034511435260">Tye <italic>et al</italic>., 2005</xref>). OC is the most abundant osteoblast-specific non-collagenous protein, with a molecular weight of 5.7 kDa. It contains a single chain of 46-50 amino acids and is involved with the binding of calcium and hydroxyapatite (<xref ref-type="bibr" rid="bibr30-0022034511435260">Hauschka <italic>et al</italic>., 1989</xref>; <xref ref-type="bibr" rid="bibr80-0022034511435260">Weinreb <italic>et al</italic>., 1990</xref>; <xref ref-type="bibr" rid="bibr17-0022034511435260">Chenu <italic>et al</italic>., 1994</xref>). Both BSP and OC play a crucial role in bone formation and bone turnover.</p>
<p>Fully matured osteoblasts are characterized by their ability to synthesize osteoid, the organic phase of the bone matrix. This osteoid becomes mineralized by the formation of hydroxyapatite (<xref ref-type="bibr" rid="bibr11-0022034511435260">Burger and Klein-Nulend, 1999</xref>). As an osteoblast becomes surrounded by its own matrix, it terminally differentiates into an osteocyte and plays a central role in cell communication and the regulation of bone remodeling (<xref ref-type="bibr" rid="bibr11-0022034511435260">Burger and Klein-Nulend, 1999</xref>). Otherwise, a mature osteoblast becomes a lining cell or undergoes apoptosis.</p>
<p>To compare the ability of growth factors to promote an osteogenic phenotype, investigators have utilized and compared MSCs for cell proliferation, ALP activity, and mineralized matrix. Results demonstrate a proliferating effect for BMPs and PGDF; however, most studies demonstrate the ability of BMPs to induce osteoblast differentiation when compared with PDGF or platelet-rich plasma (<xref ref-type="bibr" rid="bibr85-0022034511435260">Yu <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="bibr16-0022034511435260">Chaudhary <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="bibr82-0022034511435260">Wildemann <italic>et al</italic>., 2007</xref>; <xref ref-type="bibr" rid="bibr54-0022034511435260">Mooren <italic>et al</italic>., 2010</xref>). Recently, it was demonstrated that the combined use of PDGF-BB with synthetic peptides could result in an increase in proliferation and osteoblast markers, including ALP, collagen, and OC (<xref ref-type="bibr" rid="bibr79-0022034511435260">Vordemvenne <italic>et al</italic>., 2011</xref>). PDGF activates and modulates the extracellular signal-regulated kinase (ERK) pathway (<xref ref-type="bibr" rid="bibr40-0022034511435260">Kim <italic>et al</italic>., 2007</xref>; <xref ref-type="bibr" rid="bibr26-0022034511435260">Getachew <italic>et al</italic>., 2010</xref>), which has previously been shown to influence proliferation and differentiation of many cell types, including MSCs (<xref ref-type="bibr" rid="bibr86-0022034511435260">Zhang and Liu, 2002</xref>). Inhibition of PDGF receptor-beta by imatinib mesylate (IM) significantly reduced downstream Akt and ERK1/2 phosphorylation with human bone-marrow-derived MSCs <italic>in vitro</italic> (<xref ref-type="bibr" rid="bibr23-0022034511435260">Fierro <italic>et al</italic>., 2007</xref>). Results demonstrate that proliferation of MSCs was significantly reduced by IM and favored adipogenic differentiation (<xref ref-type="bibr" rid="bibr23-0022034511435260">Fierro <italic>et al</italic>., 2007</xref>). Specifically, ERK pathways can activate RUNX2 transcription factor and block PPAR-gamma during osteoblast differentiation (<xref ref-type="bibr" rid="bibr83-0022034511435260">Xiao <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="bibr41-0022034511435260">Kim <italic>et al</italic>., 2001</xref>).</p>
<p>Many investigators have demonstrated the ability of BMP to induce osteoblast differentiation, both alone or in combination with various other bone-grafting materials (Appendix Table). It is generally accepted that BMP-signaling pathways are primarily mediated through Smad proteins (<xref ref-type="bibr" rid="bibr51-0022034511435260">Massagué, 1996</xref>; <xref ref-type="bibr" rid="bibr53-0022034511435260">Miyazono <italic>et al</italic>., 2001</xref>); however, accumulating evidence demonstrates that many other pathways, including MAPK/Erk, are clearly involved in BMP2-induced osteoblast differentiation (<xref ref-type="bibr" rid="bibr69-0022034511435260">Ryoo <italic>et al</italic>., 2006</xref>). One transcription factor that plays a key role in BMP2-induced osteoblast differentiation is Dlx5 (<xref ref-type="bibr" rid="bibr68-0022034511435260">Ryoo <italic>et al</italic>., 1997</xref>). <italic>In vitro</italic> experiments have demonstrated that Dlx5 can be stimulated by endogenous BMP2, by overexpression of active forms of BMP receptors, or by overexpression of Smad1 and Smad5 proteins (<xref ref-type="bibr" rid="bibr46-0022034511435260">Lee <italic>et al</italic>., 2003</xref>). Despite a lack of complete understanding of BMP cellular pathways, addition of BMPs remains the growth factor of choice to induce MSC differentiation to osteoblasts.</p>
</sec>
<sec id="section6-0022034511435260">
<title>Osteoinductive Principle 3: Ectopic Bone Formation</title>
<p>In his original studies on osteoinduction, Marshall Urist implanted DBM particles into intramuscular defects and found new bone formation around these particles. He later defined an osteoinductive material by its ability to form bone in a non-bone defect where bone would otherwise not grow. The ability for a bone graft to induce new bone formation in an intraosseous defect does not fully reflect its true osteoinductive potential.</p>
<p>There are two ways to test osteoinduction <italic>in vivo</italic>. One is to implant subcutaneously, and the other is to implant into intramuscular defects (<xref ref-type="bibr" rid="bibr76-0022034511435260">Urist and McLean, 1952</xref>). For subcutaneous defects, a rabbit study at 4 wks with HA-TCP (<xref ref-type="bibr" rid="bibr13-0022034511435260">Catros <italic>et al</italic>., 2009</xref>) and a rat study at 3 wks with a controlled-release system for BMP encapsulated with a poly (DL-lactide-co-glycolide) (PLGA)/poly-ethyleneglycol (PEG) mixture (<xref ref-type="bibr" rid="bibr34-0022034511435260">Isobe, 1995</xref>) showed new bone formation. A comparative study also demonstrated that transplantation of osteogenically undifferentiated MSCs with BMP-2 delivery results in more extensive bone formation in subcutaneous regions than that of osteogenically differentiated or undifferentiated MSCs (<xref ref-type="bibr" rid="bibr37-0022034511435260">Kang <italic>et al</italic>., 2010</xref>).</p>
<p>Ectopic bone formation models, especially in intramuscular defects, have a much broader range of animal studies, including those in immunodeficient mice, normal mice, rats, calves, chickens, rabbits, cats, dogs, and sheep (<xref ref-type="table" rid="table2-0022034511435260">Table 2</xref>). In immunocompromised Nu/Nu mouse muscle, human DBM formulated with hyaluronic acid and cancellous/cortical bone granules were implanted and formed bone at 8 wks (<xref ref-type="bibr" rid="bibr10-0022034511435260">Braccini <italic>et al</italic>., 2005</xref>). In Swiss albino mice, Fibrin glue combined with calcium phosphate and glass ceramic was implanted into muscle and formed bone after 4 wks (<xref ref-type="bibr" rid="bibr1-0022034511435260">Abiraman <italic>et al</italic>., 2002</xref>). In a study that compared 6 bone graft substitutes (Pyrost, natural coral, Callopat, Surgibone, demineralized Surgibone, and demineralized rat bone) implanted into the abdominal musculature of rats, there was new bone formation after 3 and 6 wks in all groups (<xref ref-type="bibr" rid="bibr8-0022034511435260">Begley <italic>et al</italic>., 1995</xref>). In sheep studies, 12 post-implantation wks were required for new bone formation in osteoinductive putties combining the microstructure of biphasic calcium phosphate particles with 5 different polymeric gels (Appendix Table). The osteoinductive potential of 2 calcium phosphate ceramics was evaluated after intramuscular implantation in goats, and new bone was formed 12 wks post-implantation (Appendix Table). A full list of studies, including animals, sites of injury, lengths of studies, and materials used, is presented in <xref ref-type="table" rid="table2-0022034511435260">Table 2</xref> (<xref ref-type="bibr" rid="bibr6-0022034511435260">Barradas <italic>et al</italic>., 2011</xref>; <xref ref-type="bibr" rid="bibr29-0022034511435260">Habibovic and de Groot, 2007</xref>).</p>
<table-wrap id="table2-0022034511435260" position="float">
<label>Table 2.</label>
<caption>
<p>The <italic>in vivo</italic> Study to Test Osteoinductive Materials</p>
</caption>
<graphic alternate-form-of="table2-0022034511435260" xlink:href="10.1177_0022034511435260-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Animal</th>
<th align="center">Site</th>
<th align="center">Bone-forming Time</th>
<th align="center">Materials Types</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Swiss Webster mice weighing 12-15 g</td>
<td>Muscle</td>
<td>4-6 wks</td>
<td>60% collagen and 40% DFDBA</td>
</tr>
<tr>
<td>8- to 10-week-old female C3H/HeN mice</td>
<td>Subcutaneously and Muscle</td>
<td>2 wks</td>
<td>Oxygen carrier-enriched hydrogel combined with mesenchymal stem cell expressed BMP2</td>
</tr>
<tr>
<td>Thirty inbred male Nu/Nu mice</td>
<td>Muscle</td>
<td>8 wks</td>
<td>Human demineralized, freeze-dried bone graft</td>
</tr>
<tr>
<td>Twelve-week-old male C57Bl/6 mice</td>
<td>Muscle</td>
<td>2 wks</td>
<td>BMP2 or BMP9</td>
</tr>
<tr>
<td>Male 8-week-old ICR mice</td>
<td>Muscle</td>
<td>3 wks</td>
<td>A plasmid encoding human BMP-2 (pCAGGS-BMP-2)</td>
</tr>
<tr>
<td>10- to 12-week-old male Balb/C mice</td>
<td>Muscle</td>
<td>3 wks</td>
<td>BMP2 protein in 0.9% saline or gelatine gel</td>
</tr>
<tr>
<td>6- to 8-week-old male syngeneic C57BL/6J mice</td>
<td>Muscle</td>
<td>6 wks</td>
<td>BMP2 expression MSCs seeded on AlloDerm</td>
</tr>
<tr>
<td>9-week-old F 344/N Jcl-rnu nude rat and 9-week-old Wistar rats</td>
<td>Muscle</td>
<td>3 wks</td>
<td>Human bone morphogenetic protein-2 (BMP-2) -expressing recombinant adenoviral vector</td>
</tr>
<tr>
<td>Rats</td>
<td>Subcutaneously</td>
<td>5 wks</td>
<td>Coating deproteinized bovine bone (DBB) with a layer of calcium phosphate into which bone morphogenetic protein 2 (BMP-2) is incorporated</td>
</tr>
<tr>
<td>Six-week-old Sprague-Dawley female rat</td>
<td>Subcutaneously</td>
<td>6 wks</td>
<td>RhBMP-2 containing TCP/HAP granules</td>
</tr>
<tr>
<td>Sprague-Dawley rats</td>
<td>Muscle</td>
<td>3 wks</td>
<td>RhBMP-2 was incorporated into chitosan (CH) and hyaluronan (HY) hydrogels</td>
</tr>
<tr>
<td>Rats</td>
<td>Subcutaneous</td>
<td>3, 6, 12 wks</td>
<td>Porous calcium phosphate ceramics</td>
</tr>
<tr>
<td>5- to 7-week-old immunocompetent Sprague-Dawley rats (SD rats)</td>
<td>Muscle</td>
<td>8 wks</td>
<td>Adeno-associated virus (AAV) carrying bone morphogenetic protein2</td>
</tr>
<tr>
<td>Four-week-old syngeneic Fisher 344 male rats</td>
<td>Subcutaneously and intramuscularly (No difference)</td>
<td>3 wks</td>
<td>6-day osteogenic medium differentiation rat bone marrow cells combined with titanium-fiber mesh</td>
</tr>
<tr>
<td>Nude rat</td>
<td>Muscle</td>
<td>4 wks</td>
<td>Hydroxyapatite combined with demineralized bone matrix</td>
</tr>
<tr>
<td>Rat</td>
<td>Subcutaneous</td>
<td>5 wks</td>
<td>Titanium-alloy discs coated with a calcium phosphate and BMP-2</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Cranial periosteum</td>
<td>3, 9 wks</td>
<td>HA+BMP-2</td>
</tr>
<tr>
<td>Rabbits</td>
<td>Muscle</td>
<td>5 wks</td>
<td>Porous calcium phosphate ceramic</td>
</tr>
<tr>
<td>Adult female sheep</td>
<td>Subcutaneous and intramuscular</td>
<td>1 yr</td>
<td>Hydroxyapatite and beta-tricalcium phosphate</td>
</tr>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>12 wks</td>
<td>Calcium phosphate ceramic</td>
</tr>
<tr>
<td>Sheep</td>
<td>Muscle</td>
<td>12 wks</td>
<td>Biphasic calcium phosphate (BCP)</td>
</tr>
<tr>
<td>Adult Dutch milk goats</td>
<td>Intramuscularly</td>
<td>6, 12 wks</td>
<td>Porous Ti6Al4V material with an octacalcium phosphate (OCP) coating</td>
</tr>
<tr>
<td>Goat</td>
<td>Muscle</td>
<td>12 wk</td>
<td>3D printed bioceramic</td>
</tr>
<tr>
<td>Goat</td>
<td>Muscle</td>
<td>12 wks</td>
<td>Calcium phosphate (Ca-P) coatings on porous titanium implants</td>
</tr>
<tr>
<td>Goat</td>
<td>Muscle</td>
<td>6, 12 wks</td>
<td>Octacalcium phosphate (OCP) coating on Ti6Al4V, HA, BCP, and PEGT-PBT copolymer</td>
</tr>
<tr>
<td>Milk goat</td>
<td>Muscle</td>
<td>6, 12 wks</td>
<td>HA/BCP</td>
</tr>
<tr>
<td>Goat</td>
<td>Muscle</td>
<td>12 wks</td>
<td>Hydroxyapatite/ biphasic calcium phosphate</td>
</tr>
<tr>
<td>Dog</td>
<td>Subcutaneous/Muscle</td>
<td>4 mos</td>
<td>Coralline porous ceramics</td>
</tr>
<tr>
<td>Dog</td>
<td>Muscle</td>
<td>12 wks</td>
<td>Nano-sized CaP</td>
</tr>
<tr>
<td>Baboon</td>
<td>Muscle</td>
<td>3, 6, 9 mos</td>
<td>Porous hydroxyapatite</td>
</tr>
<tr>
<td>Baboon</td>
<td>Muscle</td>
<td>90 days</td>
<td>Porous hydroxyapatite</td>
</tr>
<tr>
<td>Rabbits/Dogs/Baboons</td>
<td>Muscle</td>
<td>90 days</td>
<td>Porous hydroxyapatite</td>
</tr>
<tr>
<td>Rabbit/Dog</td>
<td>Subcutaneous/Muscle</td>
<td>3, 6 wks/8 wks</td>
<td>Porous hydroxyapatite/poly-DL-lactide</td>
</tr>
<tr>
<td>Dog/Pig/Goat/Rabbit/Rats</td>
<td>Subcutaneous/Muscle</td>
<td>15, 30, 45, 60, 90, and 120 days</td>
<td>Porous calcium phosphate ceramics (HA/TCP)</td>
</tr>
<tr>
<td>Mice/Rats/Rabbit/Dogs</td>
<td>Subcutaneous/Muscle</td>
<td>90 days</td>
<td>BSP/HA</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Growth factors most commonly used in periodontal and oral surgery with osteoinductive potential include BMP2 and PDGF (<xref ref-type="table" rid="table2-0022034511435260">Appendix Table</xref>). Various combinations of recombinant BMP2 have been injected into rat muscle and formed new bone 9 and 21 days post-implantation (Appendix Table). A plasmid encoding human BMP2 (pCAGGS-BMP-2) was injected repeatedly (from 1 to 8 times) into the skeletal muscle of mice for 8 days and displayed new bone formation (Appendix Table). The combination of BMP2 with various biomaterials has also demonstrated ectopic bone formation <italic>in vivo</italic>. BMP-2 loaded TCP/HAP porous ceramics implanted subcutaneously for 6 wks (Appendix Table), rhBMP-2 incorporated into chitosan and hyaluronan hydrogels for 3 wks (Appendix Table), and deproteinized bovine bone coated with a layer of calcium phosphate including BMP2 for 5 wks (Appendix Table)—all have demonstrated new ectopic bone formation.</p>
<p>Although the effects of PDGF on MSC recruitment to sites of injury have been well-documented, the ability of PDGF to stimulate ectopic bone formation in intramuscular defects has not been fully demonstrated. Studies in immunocompromised mice have revealed that PDGF (<xref ref-type="bibr" rid="bibr65-0022034511435260">Ranly <italic>et al</italic>., 2005</xref>) and platelet-rich plasma (<xref ref-type="bibr" rid="bibr66-0022034511435260">Ranly <italic>et al</italic>., 2007</xref>) decrease the osteoinductivity of DBM. Furthermore, a recent study comparing the osteoinductive effects of a hydroxyapatite/TCP scaffold in combination with enamel matrix derivative or PDGF displayed no signs of osteoinduction in a murine thigh muscle model in mice (<xref ref-type="bibr" rid="bibr15-0022034511435260">Chan <italic>et al</italic>., 2011</xref>).</p>
</sec>
<sec id="section7-0022034511435260">
<title>Experimental Design of Osteoinductive Materials</title>
<p>To maximize the potential of osteoinductive biomaterials, a bone graft should be capable of (1) recruiting mesenchymal-type osteoprogenitor cells, (2) transforming an undifferentiated mesenchymal cell into a mature, bone-forming osteoblast, and (3) inducing new bone formation when implanted into intramuscular locations. With the advances in modern biology, it is possible to characterize each of these 3 principles individually.</p>
<p>The ability to test migration patterns, growth factor and cytokine release, as well as live behavioral cell migration microscopy has influenced our ability to describe recruitment of mesenchymal progenitor cells accurately. Many chemokine assays—such as transwell assays, chemotaxis assays, Boyden chambers, invasion assays, and quantitation assays with live video-microscopy—need to be fully utilized to investigate the migration patterns of osteoblast precursors accurately. Furthermore, the release of potent cytokines such as BMPs should be investigated with real-time PCR and ELISA to determine how biomaterials affect protein release of cells attached to their surfaces.</p>
<p>If a material is truly osteoinductive, it should be capable of inducing differentiation of MSCs without the use of <italic>in vitro</italic> osteogenic differentiation media. The early expression of the transcription factors Runx2 and OSX as well as osteoblast differentiation markers including collagen 1 and OC should be increased <italic>via</italic> detection by real-time PCR. Furthermore, ALP assays and mineralization staining such as von Kossa and alizarin red staining should be used.</p>
<p>Last, the implantation of bone grafts into extraskeletal locations such as muscle should be capable of bone formation <italic>in vivo</italic>. The successful combination of these 3 elements will guide the future direction of emerging biomaterials in bone regeneration.</p>
</sec>
<sec id="section8-0022034511435260">
<title>Summary of Experimental Protocol</title>
<list id="list3-0022034511435260" list-type="simple">
<list-item><p>(1) <italic>In vitro</italic> MSC migration assay.</p></list-item>
<list-item><p>(2) <italic>In vitro</italic> MSC differentiation to mature osteoblasts. Real-time PCR for Runx2, ALP, Col1, and OCN. ALP assay and calcium assay (either alizarin red or von Kossa staining).</p></list-item>
<list-item><p>(3) <italic>In vivo</italic> implantation of material injected into muscle. Bone formation should be observed in rats after 3 wks.</p></list-item>
</list>
</sec>
<sec id="section9-0022034511435260">
<title>Concluding Remarks and Perspectives</title>
<p>The perspectives discussed herein demonstrate the importance of a full understanding of biological phenomena for the application of osteoinductive biomaterials. Over the past century, major advances in biomaterials have been made, and the future field of bone grafts poses many challenges to meet the increasing demands on healthcare. Our understanding of mesenchymal cell behavior (<xref ref-type="bibr" rid="bibr70-0022034511435260">Shimono <italic>et al</italic>., 2011</xref>) will provide clues to the development of new material designs with osteoinductive ability. This will greatly widen the design parameters for the next generation of biomaterials and answer many important questions that have been raised.</p>
<p>It is currently unknown what factors guide MSCs to sites of damage through transmigration across the endothelium. The homing of MSCs has gained tremendous awareness in stem cell therapy. MSC homing is a rapid process defined by the ability of MSCs to migrate through the blood, across the endothelial vasculature, to different organs and to their bone marrow niches (<xref ref-type="bibr" rid="bibr64-0022034511435260">Quesenberry and Becker, 1998</xref>; <xref ref-type="bibr" rid="bibr43-0022034511435260">Lapidot <italic>et al</italic>., 2005</xref>). It has been proposed that injured tissues expressing specific ligands facilitate trafficking and infiltration of MSCs to sites of injury, much like recruitment of leukocytes to sites of inflammation (<xref ref-type="bibr" rid="bibr71-0022034511435260">Sordi, 2009</xref>). Leading candidates for MSC migration include chemokine SDF-1 and its interaction with CXCR4 on MSC surfaces, which allow them to relocate and regulate trafficking of MSCs to damaged tissues following a SDF1 gradient (<xref ref-type="bibr" rid="bibr12-0022034511435260">Carbajal <italic>et al</italic>., 2010</xref>). These studies, together with studies on hematopoietic cell migration, may provide the platform needed to facilitate the identification of key factors involved in MSC migration (<xref ref-type="bibr" rid="bibr72-0022034511435260">Tang <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="bibr57-0022034511435260">O’Sullivan <italic>et al</italic>., 2011</xref>). Furthermore, their interactions with cells from the immune system during inflammation could have an impact on the way MSCs contribute to the repair process in recipients <italic>in vivo</italic> (<xref ref-type="bibr" rid="bibr58-0022034511435260">Ohtaki <italic>et al</italic>., 2008</xref>; <xref ref-type="bibr" rid="bibr18-0022034511435260">Constantin <italic>et al</italic>., 2009</xref>). The importance of containing chemotactic factors for MSC migration during regenerative processes is of paramount significance. Homing MSCs represent a powerful source of multipotential cells capable of repairing damaged tissues and organs, and their migration to sites of injury is critical for future osteoinductive biomaterials.</p>
<p>The ability of osteoinductive materials themselves to recruit MSCs also raises some interesting questions. Some osteoinductive materials lack osteoinductive factors but are able to recruit and differentiate MSCs into osteoblasts <italic>in vivo</italic>. It is plausible that MSC recruitment <italic>in vivo</italic> occurs <italic>via</italic> an indirect effect by which a random MSC in contact with an osteoconductive surface releases osteoinductive factors, thereby indirectly recruiting osteoprogenitor cells. These conditions, although beneficial, need to be further investigated.</p>
<p>The field of mesenchymal differentiation to chondrocytes and osteoblasts also draws interest. It is still unclear what governs endochondral <italic>vs</italic>. intramembranous ossification during implanted defects <italic>in vivo</italic> (<xref ref-type="bibr" rid="bibr14-0022034511435260">Chan <italic>et al</italic>., 2009</xref>). Implantation with certain materials such as TCP undergoes endochondral ossification, whereas implantation with BMP2 appears to skip the chondrocyte phase and results in intramembranous ossification. A further understanding of the regulatory mechanisms of MSCs to both cell types will enhance our ability to generate more predictable results (<xref ref-type="bibr" rid="bibr52-0022034511435260">Mendez-Ferrer <italic>et al</italic>., 2010</xref>; <xref ref-type="bibr" rid="bibr61-0022034511435260">Oldershaw <italic>et al</italic>., 2010</xref>). The ability of compressive force to induce MSC differentiation needs further clarification as well. MSCs that are treated with mechanical compressive force or static stress can induce the differentiation of MSCs into osteoblasts and chondroblasts (<xref ref-type="bibr" rid="bibr84-0022034511435260">Yanagisawa <italic>et al</italic>., 2007</xref>; <xref ref-type="bibr" rid="bibr39-0022034511435260">Kim <italic>et al</italic>., 2010</xref>). The possibility of constant friction and loading on muscles injected with bone grafts may play a role in osteoblast differentiation.</p>
<p>The future field of osteoinductive biomaterials faces many challenges to meet the coming demand for bone-grafting procedures worldwide. These guidelines will ultimately facilitate their future testing and provide better long-term design for leading osteoinductive biomaterials.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supported-by">
<p>The study was funded by the ITI Foundation for the Promotion of Implantology (586_2008), Basel, Switzerland.</p>
</fn>
<fn fn-type="conflict">
<p>The authors declare no conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="supplementary-material">
<p>A supplemental appendix to this article is published electronically only at <ext-link ext-link-type="uri" xlink:href="http://jdr.sagepub.com/supplemental">http://jdr.sagepub.com/supplemental</ext-link>.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abiraman</surname><given-names>S</given-names></name>
<name><surname>Varma</surname><given-names>HK</given-names></name>
<name><surname>Umashankar</surname><given-names>PR</given-names></name>
<name><surname>John</surname><given-names>A</given-names></name>
</person-group> (<year>2002</year>). <article-title>Fibrin glue as an osteoinductive protein in a mouse model</article-title>. <source>Biomaterials</source> <volume>23</volume>:<fpage>3023</fpage>-<lpage>3031</lpage>.</citation>
</ref>
<ref id="bibr2-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ai-Aql</surname><given-names>ZS</given-names></name>
<name><surname>Alagl</surname><given-names>AS</given-names></name>
<name><surname>Graves</surname><given-names>DT</given-names></name>
<name><surname>Gerstenfeld</surname><given-names>LC</given-names></name>
<name><surname>Einhorn</surname><given-names>TA</given-names></name>
</person-group> (<year>2008</year>). <article-title>Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis</article-title>. <source>J Dent Res</source> <volume>87</volume>:<fpage>107</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr3-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez</surname><given-names>RH</given-names></name>
<name><surname>Kantarjian</surname><given-names>HM</given-names></name>
<name><surname>Cortes</surname><given-names>JE</given-names></name>
</person-group> (<year>2006</year>). <article-title>Biology of platelet-derived growth factor and its involvement in disease</article-title>. <source>Mayo Clin Proc</source> <volume>81</volume>:<fpage>1241</fpage>-<lpage>1257</lpage>.</citation>
</ref>
<ref id="bibr4-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>DG</given-names></name>
<name><surname>Burdick</surname><given-names>JA</given-names></name>
<name><surname>Langer</surname><given-names>R</given-names></name>
</person-group> (<year>2004</year>). <article-title>Materials science. Smart biomaterials</article-title>. <source>Science</source> <volume>305</volume>:<fpage>1923</fpage>-<lpage>1924</lpage>.</citation>
</ref>
<ref id="bibr5-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banerjee</surname><given-names>C</given-names></name>
<name><surname>McCabe</surname><given-names>LR</given-names></name>
<name><surname>Choi</surname><given-names>JY</given-names></name>
<name><surname>Hiebert</surname><given-names>SW</given-names></name>
<name><surname>Stein</surname><given-names>JL</given-names></name>
<name><surname>Stein</surname><given-names>GS</given-names></name>
<etal/>
</person-group>. (<year>1997</year>). <article-title>Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex</article-title>. <source>J Cell Biochem</source> <volume>66</volume>:<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr6-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barradas</surname><given-names>AM</given-names></name>
<name><surname>Yuan</surname><given-names>H</given-names></name>
<name><surname>van Blitterswijk</surname><given-names>CA</given-names></name>
<name><surname>Habibovic</surname><given-names>P</given-names></name>
</person-group> (<year>2011</year>). <article-title>Osteoinductive biomaterials: current knowledge of properties, experimental models and biological mechanisms</article-title>. <source>Eur Cell Mater</source> <volume>21</volume>:<fpage>407</fpage>-<lpage>429</lpage>.</citation>
</ref>
<ref id="bibr7-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barry</surname><given-names>FP</given-names></name>
<name><surname>Murphy</surname><given-names>JM</given-names></name>
</person-group> (<year>2004</year>). <article-title>Mesenchymal stem cells: clinical applications and biological characterization</article-title>. <source>Int J Biochem Cell Biol</source> <volume>36</volume>:<fpage>568</fpage>-<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr8-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Begley</surname><given-names>CT</given-names></name>
<name><surname>Doherty</surname><given-names>MJ</given-names></name>
<name><surname>Mollan</surname><given-names>RA</given-names></name>
<name><surname>Wilson</surname><given-names>DJ</given-names></name>
</person-group> (<year>1995</year>). <article-title>Comparative study of the osteoinductive properties of bioceramic, coral and processed bone graft substitutes</article-title>. <source>Biomaterials</source> <volume>16</volume>:<fpage>1181</fpage>-<lpage>1185</lpage>.</citation>
</ref>
<ref id="bibr9-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boskey</surname><given-names>AL</given-names></name>
<name><surname>Wright</surname><given-names>TM</given-names></name>
<name><surname>Blank</surname><given-names>RD</given-names></name>
</person-group> (<year>1999</year>). <article-title>Collagen and bone strength</article-title>. <source>J Bone Miner Res</source> <volume>14</volume>:<fpage>330</fpage>-<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr10-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braccini</surname><given-names>A</given-names></name>
<name><surname>Wendt</surname><given-names>D</given-names></name>
<name><surname>Jaquiery</surname><given-names>C</given-names></name>
<name><surname>Jakob</surname><given-names>M</given-names></name>
<name><surname>Heberer</surname><given-names>M</given-names></name>
<name><surname>Kenins</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts</article-title>. <source>Stem Cells</source> <volume>23</volume>:<fpage>1066</fpage>-<lpage>1072</lpage>.</citation>
</ref>
<ref id="bibr11-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burger</surname><given-names>EH</given-names></name>
<name><surname>Klein-Nulend</surname><given-names>J</given-names></name>
</person-group> (<year>1999</year>). <article-title>Mechanotransduction in bone—role of the lacuno-canalicular network</article-title>. <source>FASEB J</source> <volume>13</volume> (<supplement>Suppl</supplement>):<fpage>101S</fpage>-<lpage>112S</lpage>.</citation>
</ref>
<ref id="bibr12-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carbajal</surname><given-names>KS</given-names></name>
<name><surname>Schaumburg</surname><given-names>C</given-names></name>
<name><surname>Strieter</surname><given-names>R</given-names></name>
<name><surname>Kane</surname><given-names>J</given-names></name>
<name><surname>Lane</surname><given-names>TE</given-names></name>
</person-group> (<year>2010</year>). <article-title>Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>107</volume>:<fpage>11068</fpage>-<lpage>11073</lpage>.</citation>
</ref>
<ref id="bibr13-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Catros</surname><given-names>S</given-names></name>
<name><surname>Zwetyenga</surname><given-names>N</given-names></name>
<name><surname>Bareille</surname><given-names>R</given-names></name>
<name><surname>Brouillaud</surname><given-names>B</given-names></name>
<name><surname>Renard</surname><given-names>M</given-names></name>
<name><surname>Amedee</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Subcutaneous-induced membranes have no osteoinductive effect on macroporous HA-TCP in vivo</article-title>. <source>J Orthop Res</source> <volume>27</volume>:<fpage>155</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr14-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>CK</given-names></name>
<name><surname>Chen</surname><given-names>CC</given-names></name>
<name><surname>Luppen</surname><given-names>CA</given-names></name>
<name><surname>Kim</surname><given-names>JB</given-names></name>
<name><surname>DeBoer</surname><given-names>AT</given-names></name>
<name><surname>Wei</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Endochondral ossification is required for haematopoietic stem-cell niche formation</article-title>. <source>Nature</source> <volume>457</volume>:<fpage>490</fpage>-<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr15-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>RC</given-names></name>
<name><surname>Marino</surname><given-names>V</given-names></name>
<name><surname>Bartold</surname><given-names>PM</given-names></name>
</person-group> (<year>2011</year>). <article-title>The effect of Emdogain (R) and platelet-derived growth factor on the osteoinductive potential of hydroxyapatite tricalcium phosphate</article-title>. <source>Clin Oral Investig</source> [<comment>Epub ahead of print Oct 28, 2011</comment>].</citation>
</ref>
<ref id="bibr16-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaudhary</surname><given-names>LR</given-names></name>
<name><surname>Hofmeister</surname><given-names>AM</given-names></name>
<name><surname>Hruska</surname><given-names>KA</given-names></name>
</person-group> (<year>2004</year>). <article-title>Differential growth factor control of bone formation through osteoprogenitor differentiation</article-title>. <source>Bone</source> <volume>34</volume>:<fpage>402</fpage>-<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr17-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chenu</surname><given-names>C</given-names></name>
<name><surname>Colucci</surname><given-names>S</given-names></name>
<name><surname>Grano</surname><given-names>M</given-names></name>
<name><surname>Zigrino</surname><given-names>P</given-names></name>
<name><surname>Barattolo</surname><given-names>R</given-names></name>
<name><surname>Zambonin</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>1994</year>). <article-title>Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells</article-title>. <source>J Cell Biol</source> <volume>127</volume>:<fpage>1149</fpage>-<lpage>1158</lpage>.</citation>
</ref>
<ref id="bibr18-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Constantin</surname><given-names>G</given-names></name>
<name><surname>Marconi</surname><given-names>S</given-names></name>
<name><surname>Rossi</surname><given-names>B</given-names></name>
<name><surname>Angiari</surname><given-names>S</given-names></name>
<name><surname>Calderan</surname><given-names>L</given-names></name>
<name><surname>Anghileri</surname><given-names>E</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis</article-title>. <source>Stem Cells</source> <volume>27</volume>:<fpage>2624</fpage>-<lpage>2635</lpage>.</citation>
</ref>
<ref id="bibr19-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Bari</surname><given-names>C</given-names></name>
<name><surname>Dell’accio</surname><given-names>F</given-names></name>
</person-group> (<year>2008</year>). <article-title>Cell therapy: a challenge in modern medicine</article-title>. <source>Biomed Mater Eng</source> <volume>18</volume> (<supplement>1 Suppl</supplement>):<fpage>11S</fpage>-<lpage>17S</lpage>.</citation>
</ref>
<ref id="bibr20-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ducy</surname><given-names>P</given-names></name>
<name><surname>Zhang</surname><given-names>R</given-names></name>
<name><surname>Geoffroy</surname><given-names>V</given-names></name>
<name><surname>Ridall</surname><given-names>AL</given-names></name>
<name><surname>Karsenty</surname><given-names>G</given-names></name>
</person-group> (<year>1997</year>). <article-title>Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation</article-title>. <source>Cell</source> <volume>89</volume>:<fpage>747</fpage>-<lpage>754</lpage>.</citation>
</ref>
<ref id="bibr21-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ducy</surname><given-names>P</given-names></name>
<name><surname>Schinke</surname><given-names>T</given-names></name>
<name><surname>Karsenty</surname><given-names>G</given-names></name>
</person-group> (<year>2000</year>). <article-title>The osteoblast: a sophisticated fibroblast under central surveillance</article-title>. <source>Science</source> <volume>289</volume>:<fpage>1501</fpage>-<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr22-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fiedler</surname><given-names>J</given-names></name>
<name><surname>Roderer</surname><given-names>G</given-names></name>
<name><surname>Gunther</surname><given-names>KP</given-names></name>
<name><surname>Brenner</surname><given-names>RE</given-names></name>
</person-group> (<year>2002</year>). <article-title>BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells</article-title>. <source>J Cell Biochem</source> <volume>87</volume>:<fpage>305</fpage>-<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr23-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fierro</surname><given-names>F</given-names></name>
<name><surname>Illmer</surname><given-names>T</given-names></name>
<name><surname>Jing</surname><given-names>D</given-names></name>
<name><surname>Schleyer</surname><given-names>E</given-names></name>
<name><surname>Ehninger</surname><given-names>G</given-names></name>
<name><surname>Boxberger</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Inhibition of platelet-derived growth factor receptor-beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro</article-title>. <source>Cell Prolif</source> <volume>40</volume>:<fpage>355</fpage>-<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr24-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>LW</given-names></name>
<name><surname>McBride</surname><given-names>OW</given-names></name>
<name><surname>Termine</surname><given-names>JD</given-names></name>
<name><surname>Young</surname><given-names>MF</given-names></name>
</person-group> (<year>1990</year>). <article-title>Human bone sialoprotein. Deduced protein sequence and chromosomal localization</article-title>. <source>J Biol Chem</source> <volume>265</volume>:<fpage>2347</fpage>-<lpage>2351</lpage>.</citation>
</ref>
<ref id="bibr25-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedenstein</surname><given-names>AJ</given-names></name>
<name><surname>Chailakhjan</surname><given-names>RK</given-names></name>
<name><surname>Lalykina</surname><given-names>KS</given-names></name>
</person-group> (<year>1970</year>). <article-title>The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells</article-title>. <source>Cell Tissue Kinet</source> <volume>3</volume>:<fpage>393</fpage>-<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr26-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Getachew</surname><given-names>R</given-names></name>
<name><surname>Ballinger</surname><given-names>ML</given-names></name>
<name><surname>Burch</surname><given-names>ML</given-names></name>
<name><surname>Reid</surname><given-names>JJ</given-names></name>
<name><surname>Khachigian</surname><given-names>LM</given-names></name>
<name><surname>Wight</surname><given-names>TN</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL</article-title>. <source>Endocrinology</source> <volume>151</volume>:<fpage>4356</fpage>-<lpage>4367</lpage>.</citation>
</ref>
<ref id="bibr27-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giannoudis</surname><given-names>PV</given-names></name>
<name><surname>Dinopoulos</surname><given-names>H</given-names></name>
<name><surname>Tsiridis</surname><given-names>E</given-names></name>
</person-group> (<year>2005</year>). <article-title>Bone substitutes: an update</article-title>. <source>Injury</source> <volume>36</volume>(<supplement>Suppl 3</supplement>):<fpage>20</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr28-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonnerman</surname><given-names>KN</given-names></name>
<name><surname>Brown</surname><given-names>LS</given-names></name>
<name><surname>Chu</surname><given-names>TM</given-names></name>
</person-group> (<year>2006</year>). <article-title>Effects of growth factors on cell migration and alkaline phosphatase release</article-title>. <source>Biomed Sci Instrum</source> <volume>42</volume>:<fpage>60</fpage>-<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr29-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Habibovic</surname><given-names>P</given-names></name>
<name><surname>de Groot</surname><given-names>K</given-names></name>
</person-group> (<year>2007</year>). <article-title>Osteoinductive biomaterials–properties and relevance in bone repair</article-title>. <source>J Tissue Eng Regen Med</source> <volume>1</volume>:<fpage>25</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr30-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hauschka</surname><given-names>PV</given-names></name>
<name><surname>Lian</surname><given-names>JB</given-names></name>
<name><surname>Cole</surname><given-names>DE</given-names></name>
<name><surname>Gundberg</surname><given-names>CM</given-names></name>
</person-group> (<year>1989</year>). <article-title>Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone</article-title>. <source>Physiol Rev</source> <volume>69</volume>:<fpage>990</fpage>-<lpage>1047</lpage>.</citation>
</ref>
<ref id="bibr31-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heinzel</surname><given-names>K</given-names></name>
<name><surname>Benz</surname><given-names>C</given-names></name>
<name><surname>Bleul</surname><given-names>CC</given-names></name>
</person-group> (<year>2007</year>). <article-title>A silent chemokine receptor regulates steady-state leukocyte homing in vivo</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>104</volume>:<fpage>8421</fpage>-<lpage>8426</lpage>.</citation>
</ref>
<ref id="bibr32-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horwitz</surname><given-names>EM</given-names></name>
<name><surname>Le Blanc</surname><given-names>K</given-names></name>
<name><surname>Dominici</surname><given-names>M</given-names></name>
<name><surname>Mueller</surname><given-names>I</given-names></name>
<name><surname>Slaper-Cortenbach</surname><given-names>I</given-names></name>
<name><surname>Marini</surname><given-names>FC</given-names></name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement</article-title>. <source>Cytotherapy</source> <volume>7</volume>:<fpage>393</fpage>-<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr33-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huggins</surname><given-names>CB</given-names></name>
</person-group> (<year>1931</year>). <article-title>The phosphatase activity of transplants of the epithelium of the urinary bladder to the abdominal wall producing heterotopic ossification</article-title>. <source>Biochem J</source> <volume>25</volume>:<fpage>728</fpage>-<lpage>732</lpage>.</citation>
</ref>
<ref id="bibr34-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isobe</surname><given-names>M</given-names></name>
</person-group> (<year>1995</year>). <article-title>[Characteristics and osteoinductive activity of bone morphogenetic protein (BMP) encapsulated with poly (DL-lactide-co-glycolide)]</article-title>. <source>Kokubyo Gakkai Zasshi</source> <volume>62</volume>:<fpage>506</fpage>-<lpage>512</lpage> [<comment>in Japanese</comment>].</citation>
</ref>
<ref id="bibr35-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jabbarzadeh</surname><given-names>E</given-names></name>
<name><surname>Starnes</surname><given-names>T</given-names></name>
<name><surname>Khan</surname><given-names>YM</given-names></name>
<name><surname>Jiang</surname><given-names>T</given-names></name>
<name><surname>Wirtel</surname><given-names>AJ</given-names></name>
<name><surname>Deng</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell transplantation approach</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>105</volume>:<fpage>11099</fpage>-<lpage>11104</lpage>.</citation>
</ref>
<ref id="bibr36-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaigler</surname><given-names>D</given-names></name>
<name><surname>Avila</surname><given-names>G</given-names></name>
<name><surname>Wisner-Lynch</surname><given-names>L</given-names></name>
<name><surname>Nevins</surname><given-names>ML</given-names></name>
<name><surname>Nevins</surname><given-names>M</given-names></name>
<name><surname>Rasperini</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Platelet-derived growth factor applications in periodontal and peri-implant bone regeneration</article-title>. <source>Expert Opin Biol Ther</source> <volume>11</volume>:<fpage>375</fpage>-<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr37-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>JM</given-names></name>
<name><surname>Kang</surname><given-names>SW</given-names></name>
<name><surname>La</surname><given-names>WG</given-names></name>
<name><surname>Yang</surname><given-names>YS</given-names></name>
<name><surname>Kim</surname><given-names>BS</given-names></name>
</person-group> (<year>2010</year>). <article-title>Enhancement of in vivo bone regeneration efficacy of osteogenically undifferentiated human cord blood mesenchymal stem cells</article-title>. <source>J Biomed Mater Res A</source> <volume>93</volume>:<fpage>666</fpage>-<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr38-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kao</surname><given-names>ST</given-names></name>
<name><surname>Scott</surname><given-names>DD</given-names></name>
</person-group> (<year>2007</year>). <article-title>A review of bone substitutes</article-title>. <source>Oral Maxillofac Surg Clin North Am</source> <volume>19</volume>:<fpage>513</fpage>-<lpage>521</lpage>, <fpage>vi</fpage>.</citation>
</ref>
<ref id="bibr39-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>IS</given-names></name>
<name><surname>Song</surname><given-names>YM</given-names></name>
<name><surname>Hwang</surname><given-names>SJ</given-names></name>
</person-group> (<year>2010</year>). <article-title>Osteogenic responses of human mesenchymal stromal cells to static stretch</article-title>. <source>J Dent Res</source> <volume>89</volume>:<fpage>1129</fpage>-<lpage>1134</lpage>.</citation>
</ref>
<ref id="bibr40-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SJ</given-names></name>
<name><surname>Kim</surname><given-names>SY</given-names></name>
<name><surname>Kwon</surname><given-names>CH</given-names></name>
<name><surname>Kim</surname><given-names>YK</given-names></name>
</person-group> (<year>2007</year>). <article-title>Differential effect of FGF and PDGF on cell proliferation and migration in osteoblastic cells</article-title>. <source>Growth Factors</source> <volume>25</volume>:<fpage>77</fpage>-<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr41-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SW</given-names></name>
<name><surname>Muise</surname><given-names>AM</given-names></name>
<name><surname>Lyons</surname><given-names>PJ</given-names></name>
<name><surname>Ro</surname><given-names>HS</given-names></name>
</person-group> (<year>2001</year>). <article-title>Regulation of adipogenesis by a transcriptional repressor that modulates MAPK activation</article-title>. <source>J Biol Chem</source> <volume>276</volume>:<fpage>10199</fpage>-<lpage>10206</lpage>.</citation>
</ref>
<ref id="bibr42-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langer</surname><given-names>R</given-names></name>
</person-group> (<year>2009</year>). <article-title>Perspectives and challenges in tissue engineering and regenerative medicine</article-title>. <source>Adv Mater</source> <volume>21</volume>:<fpage>3235</fpage>-<lpage>3236</lpage>.</citation>
</ref>
<ref id="bibr43-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lapidot</surname><given-names>T</given-names></name>
<name><surname>Dar</surname><given-names>A</given-names></name>
<name><surname>Kollet</surname><given-names>O</given-names></name>
</person-group> (<year>2005</year>). <article-title>How do stem cells find their way home?</article-title> <source>Blood</source> <volume>106</volume>:<fpage>1901</fpage>-<lpage>1910</lpage>.</citation>
</ref>
<ref id="bibr44-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazarus</surname><given-names>HM</given-names></name>
<name><surname>Haynesworth</surname><given-names>SE</given-names></name>
<name><surname>Gerson</surname><given-names>SL</given-names></name>
<name><surname>Rosenthal</surname><given-names>NS</given-names></name>
<name><surname>Caplan</surname><given-names>AI</given-names></name>
</person-group> (<year>1995</year>). <article-title>Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use</article-title>. <source>Bone Marrow Transplant</source> <volume>16</volume>:<fpage>557</fpage>-<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr45-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazarus</surname><given-names>HM</given-names></name>
<name><surname>Koc</surname><given-names>ON</given-names></name>
<name><surname>Devine</surname><given-names>SM</given-names></name>
<name><surname>Curtin</surname><given-names>P</given-names></name>
<name><surname>Maziarz</surname><given-names>RT</given-names></name>
<name><surname>Holland</surname><given-names>HK</given-names></name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients</article-title>. <source>Biol Blood Marrow Transplant</source> <volume>11</volume>:<fpage>389</fpage>-<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr46-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>MH</given-names></name>
<name><surname>Kim</surname><given-names>YJ</given-names></name>
<name><surname>Kim</surname><given-names>HJ</given-names></name>
<name><surname>Park</surname><given-names>HD</given-names></name>
<name><surname>Kang</surname><given-names>AR</given-names></name>
<name><surname>Kyung</surname><given-names>HM</given-names></name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression</article-title>. <source>J Biol Chem</source> <volume>278</volume>:<fpage>34387</fpage>-<lpage>34394</lpage>.</citation>
</ref>
<ref id="bibr47-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levander</surname><given-names>G</given-names></name>
</person-group> (<year>1938</year>). <article-title>A study of bone regeneration</article-title>. <source>Surg Gynecol Obstet</source> <volume>67</volume>:<fpage>705</fpage>-<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr48-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Cui</surname><given-names>Y</given-names></name>
<name><surname>McIlmurray</surname><given-names>L</given-names></name>
<name><surname>Allen</surname><given-names>WE</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
</person-group> (<year>2005</year>). <article-title>rhBMP-2, rhVEGF (165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells</article-title>. <source>J Orthop Res</source> <volume>23</volume>:<fpage>680</fpage>-<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr49-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lissenberg-Thunnissen</surname><given-names>SN</given-names></name>
<name><surname>de Gorter</surname><given-names>DJ</given-names></name>
<name><surname>Sier</surname><given-names>CF</given-names></name>
<name><surname>Schipper</surname><given-names>IB</given-names></name>
</person-group> (<year>2011</year>). <article-title>Use and efficacy of bone morphogenetic proteins in fracture healing</article-title>. <source>Int Orthop</source> <volume>35</volume>:<fpage>1271</fpage>-<lpage>1280</lpage>.</citation>
</ref>
<ref id="bibr50-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>ZJ</given-names></name>
<name><surname>Zhuge</surname><given-names>Y</given-names></name>
<name><surname>Velazquez</surname><given-names>OC</given-names></name>
</person-group> (<year>2009</year>). <article-title>Trafficking and differentiation of mesenchymal stem cells</article-title>. <source>J Cell Biochem</source> <volume>106</volume>:<fpage>984</fpage>-<lpage>991</lpage>.</citation>
</ref>
<ref id="bibr51-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Massagué</surname><given-names>J</given-names></name>
</person-group> (<year>1996</year>). <article-title>TGFbeta signaling: receptors, transducers, and Mad proteins</article-title>. <source>Cell</source> <volume>85</volume>:<fpage>947</fpage>-<lpage>950</lpage>.</citation>
</ref>
<ref id="bibr52-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mendez-Ferrer</surname><given-names>S</given-names></name>
<name><surname>Michurina</surname><given-names>TV</given-names></name>
<name><surname>Ferraro</surname><given-names>F</given-names></name>
<name><surname>Mazloom</surname><given-names>AR</given-names></name>
<name><surname>Macarthur</surname><given-names>BD</given-names></name>
<name><surname>Lira</surname><given-names>SA</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Mesenchymal and haematopoietic stem cells form a unique bone marrow niche</article-title>. <source>Nature</source> <volume>466</volume>:<fpage>829</fpage>-<lpage>834</lpage>.</citation>
</ref>
<ref id="bibr53-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyazono</surname><given-names>K</given-names></name>
<name><surname>Kusanagi</surname><given-names>K</given-names></name>
<name><surname>Inoue</surname><given-names>H</given-names></name>
</person-group> (<year>2001</year>). <article-title>Divergence and convergence of TGF-beta/BMP signaling</article-title>. <source>J Cell Physiol</source> <volume>187</volume>:<fpage>265</fpage>-<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr54-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mooren</surname><given-names>RE</given-names></name>
<name><surname>Hendriks</surname><given-names>EJ</given-names></name>
<name><surname>van den Beucken</surname><given-names>JJ</given-names></name>
<name><surname>Merkx</surname><given-names>MA</given-names></name>
<name><surname>Meijer</surname><given-names>GJ</given-names></name>
<name><surname>Jansen</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>The effect of platelet-rich plasma <italic>in vitro</italic> on primary cells: rat osteoblast-like cells and human endothelial cells</article-title>. <source>Tissue Eng Part A</source> <volume>16</volume>:<fpage>3159</fpage>-<lpage>3172</lpage>.</citation>
</ref>
<ref id="bibr55-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakashima</surname><given-names>K</given-names></name>
<name><surname>Zhou</surname><given-names>X</given-names></name>
<name><surname>Kunkel</surname><given-names>G</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Deng</surname><given-names>JM</given-names></name>
<name><surname>Behringer</surname><given-names>RR</given-names></name>
<etal/>
</person-group>. (<year>2002</year>). <article-title>The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation</article-title>. <source>Cell</source> <volume>108</volume>:<fpage>17</fpage>-<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr56-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nombela-Arrieta</surname><given-names>C</given-names></name>
<name><surname>Ritz</surname><given-names>J</given-names></name>
<name><surname>Silberstein</surname><given-names>LE</given-names></name>
</person-group> (<year>2011</year>). <article-title>The elusive nature and function of mesenchymal stem cells</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>12</volume>:<fpage>126</fpage>-<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr57-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Sullivan</surname><given-names>J</given-names></name>
<name><surname>D’Arcy</surname><given-names>S</given-names></name>
<name><surname>Barry</surname><given-names>FP</given-names></name>
<name><surname>Murphy</surname><given-names>JM</given-names></name>
<name><surname>Coleman</surname><given-names>CM</given-names></name>
</person-group> (<year>2011</year>). <article-title>Mesenchymal chondroprogenitor cell origin and therapeutic potential</article-title>. <source>Stem Cell Res Ther</source> <volume>2</volume>:<fpage>8</fpage>.</citation>
</ref>
<ref id="bibr58-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohtaki</surname><given-names>H</given-names></name>
<name><surname>Ylostalo</surname><given-names>JH</given-names></name>
<name><surname>Foraker</surname><given-names>JE</given-names></name>
<name><surname>Robinson</surname><given-names>AP</given-names></name>
<name><surname>Reger</surname><given-names>RL</given-names></name>
<name><surname>Shioda</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2008</year>). <article-title>Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>105</volume>:<fpage>14638</fpage>-<lpage>14643</lpage>.</citation>
</ref>
<ref id="bibr59-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oldberg</surname><given-names>A</given-names></name>
<name><surname>Franzen</surname><given-names>A</given-names></name>
<name><surname>Heinegard</surname><given-names>D</given-names></name>
</person-group> (<year>1986</year>). <article-title>Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>83</volume>:<fpage>8819</fpage>-<lpage>8823</lpage>.</citation>
</ref>
<ref id="bibr60-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oldberg</surname><given-names>A</given-names></name>
<name><surname>Franzen</surname><given-names>A</given-names></name>
<name><surname>Heinegard</surname><given-names>D</given-names></name>
</person-group> (<year>1988</year>). <article-title>The primary structure of a cell-binding bone sialoprotein</article-title>. <source>J Biol Chem</source> <volume>263</volume>:<fpage>19430</fpage>-<lpage>19432</lpage>.</citation>
</ref>
<ref id="bibr61-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oldershaw</surname><given-names>RA</given-names></name>
<name><surname>Baxter</surname><given-names>MA</given-names></name>
<name><surname>Lowe</surname><given-names>ET</given-names></name>
<name><surname>Bates</surname><given-names>N</given-names></name>
<name><surname>Grady</surname><given-names>LM</given-names></name>
<name><surname>Soncin</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Directed differentiation of human embryonic stem cells toward chondrocytes</article-title>. <source>Nat Biotechnol</source> <volume>28</volume>:<fpage>1187</fpage>-<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr62-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Phinney</surname><given-names>DG</given-names></name>
<name><surname>Prockop</surname><given-names>DJ</given-names></name>
</person-group> (<year>2007</year>). <article-title>Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views</article-title>. <source>Stem Cells</source> <volume>25</volume>:<fpage>2896</fpage>-<lpage>2902</lpage>.</citation>
</ref>
<ref id="bibr63-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Place</surname><given-names>ES</given-names></name>
<name><surname>Evans</surname><given-names>ND</given-names></name>
<name><surname>Stevens</surname><given-names>MM</given-names></name>
</person-group> (<year>2009</year>). <article-title>Complexity in biomaterials for tissue engineering</article-title>. <source>Nat Mater</source> <volume>8</volume>:<fpage>457</fpage>-<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr64-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quesenberry</surname><given-names>PJ</given-names></name>
<name><surname>Becker</surname><given-names>PS</given-names></name>
</person-group> (<year>1998</year>). <article-title>Stem cell homing: rolling, crawling, and nesting</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>95</volume>:<fpage>15155</fpage>-<lpage>15157</lpage>.</citation>
</ref>
<ref id="bibr65-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ranly</surname><given-names>DM</given-names></name>
<name><surname>McMillan</surname><given-names>J</given-names></name>
<name><surname>Keller</surname><given-names>T</given-names></name>
<name><surname>Lohmann</surname><given-names>CH</given-names></name>
<name><surname>Meunch</surname><given-names>T</given-names></name>
<name><surname>Cochran</surname><given-names>DL</given-names></name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Platelet-derived growth factor inhibits demineralized bone matrix-induced intramuscular cartilage and bone formation. A study of immunocompromised mice</article-title>. <source>J Bone Joint Surg Am</source> <volume>87</volume>:<fpage>2052</fpage>-<lpage>2064</lpage>.</citation>
</ref>
<ref id="bibr66-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ranly</surname><given-names>DM</given-names></name>
<name><surname>Lohmann</surname><given-names>CH</given-names></name>
<name><surname>Andreacchio</surname><given-names>D</given-names></name>
<name><surname>Boyan</surname><given-names>BD</given-names></name>
<name><surname>Schwartz</surname><given-names>Z</given-names></name>
</person-group> (<year>2007</year>). <article-title>Platelet-rich plasma inhibits demineralized bone matrix-induced bone formation in nude mice</article-title>. <source>J Bone Joint Surg Am</source> <volume>89</volume>:<fpage>139</fpage>-<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr67-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ronnstrand</surname><given-names>L</given-names></name>
<name><surname>Heldin</surname><given-names>CH</given-names></name>
</person-group> (<year>2001</year>). <article-title>Mechanisms of platelet-derived growth factor-induced chemotaxis</article-title>. <source>Int J Cancer</source> <volume>91</volume>:<fpage>757</fpage>-<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr68-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryoo</surname><given-names>HM</given-names></name>
<name><surname>Hoffmann</surname><given-names>HM</given-names></name>
<name><surname>Beumer</surname><given-names>T</given-names></name>
<name><surname>Frenkel</surname><given-names>B</given-names></name>
<name><surname>Towler</surname><given-names>DA</given-names></name>
<name><surname>Stein</surname><given-names>GS</given-names></name>
<etal/>
</person-group>. (<year>1997</year>). <article-title>Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression</article-title>. <source>Mol Endocrinol</source> <volume>11</volume>:<fpage>1681</fpage>-<lpage>1694</lpage>.</citation>
</ref>
<ref id="bibr69-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryoo</surname><given-names>HM</given-names></name>
<name><surname>Lee</surname><given-names>MH</given-names></name>
<name><surname>Kim</surname><given-names>YJ</given-names></name>
</person-group> (<year>2006</year>). <article-title>Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells</article-title>. <source>Gene</source> <volume>366</volume>:<fpage>51</fpage>-<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr70-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimono</surname><given-names>K</given-names></name>
<name><surname>Tung</surname><given-names>WE</given-names></name>
<name><surname>Macolino</surname><given-names>C</given-names></name>
<name><surname>Chi</surname><given-names>AH</given-names></name>
<name><surname>Didizian</surname><given-names>JH</given-names></name>
<name><surname>Mundy</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2011</year>). <article-title>Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists</article-title>. <source>Nat Med</source> <volume>17</volume>:<fpage>454</fpage>-<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr71-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sordi</surname><given-names>V</given-names></name>
</person-group> (<year>2009</year>). <article-title>Mesenchymal stem cell homing capacity</article-title>. <source>Transplantation</source> <volume>87</volume>(<supplement>9 Suppl</supplement>):<fpage>42S</fpage>-<lpage>45S</lpage>.</citation>
</ref>
<ref id="bibr72-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>X</given-names></name>
<name><surname>Lei</surname><given-names>W</given-names></name>
<name><surname>Pang</surname><given-names>L</given-names></name>
<name><surname>Wan</surname><given-names>C</given-names></name>
<name><surname>Shi</surname><given-names>Z</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). <article-title>TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation</article-title>. <source>Nat Med</source> <volume>15</volume>:<fpage>757</fpage>-<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr73-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tenenbaum</surname><given-names>HC</given-names></name>
</person-group> (<year>1987</year>). <article-title>Levamisole and inorganic pyrophosphate inhibit beta-glycerophosphate induced mineralization of bone formed in vitro</article-title>. <source>Bone Miner</source> <volume>3</volume>:<fpage>13</fpage>-<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr74-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tye</surname><given-names>CE</given-names></name>
<name><surname>Hunter</surname><given-names>GK</given-names></name>
<name><surname>Goldberg</surname><given-names>HA</given-names></name>
</person-group> (<year>2005</year>). <article-title>Identification of the type I collagen-binding domain of bone sialoprotein and characterization of the mechanism of interaction</article-title>. <source>J Biol Chem</source> <volume>280</volume>:<fpage>13487</fpage>-<lpage>13492</lpage>.</citation>
</ref>
<ref id="bibr75-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urist</surname><given-names>MR</given-names></name>
</person-group> (<year>1965</year>). <article-title>Bone: formation by autoinduction</article-title>. <source>Science</source> <volume>150</volume>(<issue>3698</issue>):<fpage>893</fpage>-<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr76-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urist</surname><given-names>MR</given-names></name>
<name><surname>McLean</surname><given-names>FC</given-names></name>
</person-group> (<year>1952</year>). <article-title>Osteogenetic potency and new-bone formation by induction in transplants to the anterior chamber of the eye</article-title>. <source>J Bone Joint Surg Am</source> <volume>34</volume>(<issue>A</issue>):<fpage>443</fpage>-<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr77-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urist</surname><given-names>MR</given-names></name>
<name><surname>Strates</surname><given-names>BS</given-names></name>
</person-group> (<year>1971</year>). <article-title>Bone morphogenetic protein</article-title>. <source>J Dent Res</source> <volume>50</volume>:<fpage>1392</fpage>-<lpage>1406</lpage>.</citation>
</ref>
<ref id="bibr78-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urist</surname><given-names>MR</given-names></name>
<name><surname>Silverman</surname><given-names>BF</given-names></name>
<name><surname>Buring</surname><given-names>K</given-names></name>
<name><surname>Dubuc</surname><given-names>FL</given-names></name>
<name><surname>Rosenberg</surname><given-names>JM</given-names></name>
</person-group> (<year>1967</year>). <article-title>The bone induction principle</article-title>. <source>Clin Orthop Relat Res</source> <volume>53</volume>:<fpage>243</fpage>-<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr79-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vordemvenne</surname><given-names>T</given-names></name>
<name><surname>Paletta</surname><given-names>JR</given-names></name>
<name><surname>Hartensuer</surname><given-names>R</given-names></name>
<name><surname>Pap</surname><given-names>T</given-names></name>
<name><surname>Raschke</surname><given-names>MJ</given-names></name>
<name><surname>Ochman</surname><given-names>S</given-names></name>
</person-group> (<year>2011</year>). <article-title>Cooperative effects in differentiation and proliferation between PDGF-BB and matrix derived synthetic peptides in human osteoblasts</article-title>. <source>BMC Musculoskelet Disord</source> <volume>12</volume>:<fpage>263</fpage>.</citation>
</ref>
<ref id="bibr80-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinreb</surname><given-names>M</given-names></name>
<name><surname>Shinar</surname><given-names>D</given-names></name>
<name><surname>Rodan</surname><given-names>GA</given-names></name>
</person-group> (<year>1990</year>). <article-title>Different patterns of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization</article-title>. <source>J Bone Miner Res</source> <volume>5</volume>:<fpage>831</fpage>-<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr81-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wennberg</surname><given-names>C</given-names></name>
<name><surname>Hessle</surname><given-names>L</given-names></name>
<name><surname>Lundberg</surname><given-names>P</given-names></name>
<name><surname>Mauro</surname><given-names>S</given-names></name>
<name><surname>Narisawa</surname><given-names>S</given-names></name>
<name><surname>Lerner</surname><given-names>UH</given-names></name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice</article-title>. <source>J Bone Miner Res</source> <volume>15</volume>:<fpage>1879</fpage>-<lpage>1888</lpage>.</citation>
</ref>
<ref id="bibr82-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wildemann</surname><given-names>B</given-names></name>
<name><surname>Burkhardt</surname><given-names>N</given-names></name>
<name><surname>Luebberstedt</surname><given-names>M</given-names></name>
<name><surname>Vordemvenne</surname><given-names>T</given-names></name>
<name><surname>Schmidmaier</surname><given-names>G</given-names></name>
</person-group> (<year>2007</year>). <article-title>Proliferating and differentiating effects of three different growth factors on pluripotent mesenchymal cells and osteoblast like cells</article-title>. <source>J Orthop Surg Res</source> <volume>2</volume>:<fpage>27</fpage>.</citation>
</ref>
<ref id="bibr83-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>G</given-names></name>
<name><surname>Jiang</surname><given-names>D</given-names></name>
<name><surname>Thomas</surname><given-names>P</given-names></name>
<name><surname>Benson</surname><given-names>MD</given-names></name>
<name><surname>Guan</surname><given-names>K</given-names></name>
<name><surname>Karsenty</surname><given-names>G</given-names></name>
<etal/>
</person-group>. (<year>2000</year>). <article-title>MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1</article-title>. <source>J Biol Chem</source> <volume>275</volume>:<fpage>4453</fpage>-<lpage>4459</lpage>.</citation>
</ref>
<ref id="bibr84-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yanagisawa</surname><given-names>M</given-names></name>
<name><surname>Suzuki</surname><given-names>N</given-names></name>
<name><surname>Mitsui</surname><given-names>N</given-names></name>
<name><surname>Koyama</surname><given-names>Y</given-names></name>
<name><surname>Otsuka</surname><given-names>K</given-names></name>
<name><surname>Shimizu</surname><given-names>N</given-names></name>
</person-group> (<year>2007</year>). <article-title>Effects of compressive force on the differentiation of pluripotent mesenchymal cells</article-title>. <source>Life Sci</source> <volume>81</volume>:<fpage>405</fpage>-<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr85-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname><given-names>X</given-names></name>
<name><surname>Hsieh</surname><given-names>SC</given-names></name>
<name><surname>Bao</surname><given-names>W</given-names></name>
<name><surname>Graves</surname><given-names>DT</given-names></name>
</person-group> (<year>1997</year>). <article-title>Temporal expression of PDGF receptors and PDGF regulatory effects on osteoblastic cells in mineralizing cultures</article-title>. <source>Am J Physiol</source> <volume>272</volume>(<issue>5</issue> <supplement>Pt 1</supplement>):<fpage>C1709</fpage>-<lpage>C1716</lpage>.</citation>
</ref>
<ref id="bibr86-0022034511435260">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Liu</surname><given-names>HT</given-names></name>
</person-group> (<year>2002</year>). <article-title>MAPK signal pathways in the regulation of cell proliferation in mammalian cells</article-title>. <source>Cell Res</source> <volume>12</volume>:<fpage>9</fpage>-<lpage>18</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>